SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/10/24 vTv Therapeutics Inc. S-3 5:756K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: S-3 Registration Statement - Securities for a HTML 399K Transaction 2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 252K 3: EX-5.1 Opinion of Counsel re: Legality HTML 32K 4: EX-23.1 Consent of Expert or Counsel HTML 5K 5: EX-FILING FEES Filing Fees HTML 54K
EX-FILING FEES |
Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
vTv Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered(1) |
Proposed Price Per |
Maximum Price(3) |
Fee Rate |
Amount of Registration Fee | |||||||||
Newly Registered Securities | ||||||||||||||||
Fees to be Paid |
Equity | Class A Common Stock, par value $0.01 per share |
— | — | — | — | — | — | ||||||||
Equity | Preferred Stock | — | — | — | — | — | — | |||||||||
Debt | Debt Securities | — | — | — | — | — | — | |||||||||
Other | Warrants | — | — | — | — | — | — | |||||||||
Other | Rights | — | — | — | — | — | — | |||||||||
Other | Units | — | — | — | — | — | — | |||||||||
Unallocated (Universal) Shelf | — | Rule 457(o) | — | — | $250,000,000 | 0.00014760 | $36,900 | |||||||||
Fees Previously Paid |
— | — | — | — | — | — | — | — | ||||||||
Total Offering Amounts |
$250,000,000 | $36,900 | ||||||||||||||
Total Fees Previously Paid |
— | |||||||||||||||
Total Fee Offsets |
$25,287.63 | |||||||||||||||
Net Fees Due |
$11,612.37 |
(1) | There are being registered hereunder an indeterminate number of each identified class of securities of vTv Therapeutics, Inc., which securities may be offered and sold, on a primary basis, in such amount as shall result in an aggregate public offering price for all securities of $250,000,000 after the date hereof. The securities registered hereunder also include such indeterminate amount of debt securities and shares of Class A common stock and shares of preferred stock as may be issued upon conversion or exchange for any other debt securities or preferred stock that provide for conversion or exchange into other securities being registered hereunder. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall be deemed to cover an indeterminate number of additional securities to be offered as a result of share splits, share dividends or similar transactions. |
(2) | With regard to the securities included in the offering made hereby, the proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance of the securities registered by this Registration Statement. Prices, when determined, may be in U.S. dollars or the equivalent thereof in one or more foreign currencies, foreign currency units or composite currencies. If any debt securities or shares of preferred stock are issued at an original issue discount, then the amount registered will include the principal or liquidation amount of such securities measured by the initial offering price thereof. |
(3) | The Registrant previously filed a Registration Statement on Form S-3 with the Securities and Exchange Commission on March 18, 2021 (File No. 333-254445), which was subsequently amended on April 9, 2021 and declared effective on April 20, 2021 (the “Prior Registration Statement”), that registered an aggregate of $250,000,000 of shares of Class A Common Stock to be offered by the Registrant from time to time, for which the Registrant paid a filing fee of $27,275. In connection therewith, $231,783,991.85 of the securities remain unsold, leaving $25,287.63 in previously paid fees available for future offset (calculated at the fee rate in effect on the filing date of the Prior Registration Statement). In accordance with Rule 457(p) under the Securities Act, the Registrant is using $25,287.63 of the unused filing fees to offset the filing fee payable in connection with this filing. Accordingly, a registration fee of $11,612.37 is due to be paid at this time. Concurrently with the effectiveness of this registration statement, any offering of unsold securities pursuant to the Prior Registration Statement is hereby terminated. |
Table 2: Fee Offset Claims and Sources
Registrant or Filer Name |
Form or Filing Type |
File Number |
Initial Filing Date |
Filing Date |
Fee Offset |
Security Type Associate with Fee Offset Claimed |
Security Title Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed |
Fee Paid with Fee Offset Source | ||||||||||||
Rule 457(p) | ||||||||||||||||||||||
Fee Offset Claims |
S-3 | 333-254445 | March 18, 2021 | $25,287.63 | Equity | Class A common stock, par value $0.01 per share |
N/A | $231,783,991.85(1) | ||||||||||||||
Fee Offset Sources |
S-3 | 333-254445 | March 18, 2021 | $25,287.63(1) |
(1) | See Note (3) under Table 1 above. |
This ‘S-3’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 4/10/24 | |||
4/20/21 | EFFECT | |||
4/9/21 | S-3/A | |||
3/18/21 | DEF 14A, DEFA14A, S-3 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/26/24 vTv Therapeutics Inc. 8-K:8 3/25/24 10:139K 3/14/24 vTv Therapeutics Inc. 8-K:5 3/13/24 10:140K 3/13/24 vTv Therapeutics Inc. 10-K 12/31/23 102:18M 2/28/24 vTv Therapeutics Inc. 8-K:1,2,8,9 2/28/24 12:419K Donnelley … Solutions/FA 2/28/24 vTv Therapeutics Inc. 8-K:1,5,8,9 2/23/24 17:663K Donnelley … Solutions/FA 3/03/22 vTv Therapeutics Inc. 8-K:5,9 2/27/22 11:361K Paul Weiss Ri… LLP 01/FA 5/05/21 vTv Therapeutics Inc. 8-K:2,5,9 5/05/21 3:466K ActiveDisclosure/FA 8/04/15 vTv Therapeutics Inc. 8-K:1,3,5,9 7/29/15 10:1.9M Broadridge Fin’l… Inc/FA 7/30/15 vTv Therapeutics Inc. 8-A12B 1:14K Broadridge Fin’l… Inc/FA |